Stock Updates

Is this Large Market Cap Stock target price reasonable for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)?

The company in question is, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) currently with a stock price of 35.45 (-1.99% today). The market cap for Alnylam Pharmaceuticals, Inc. is 3276.28, and is in the sector Healthcare, and Biotechnology industry. The target price for Alnylam Pharmaceuticals, Inc. is 73.53. Currently Alnylam Pharmaceuticals, Inc. is trading with a P/E of *TBA, and a forward P/E of *TBA. Average volume for Alnylam Pharmaceuticals, Inc. is 1055.16 and so far today it is 882581.

Performance in the last year for Alnylam Pharmaceuticals, Inc. has been -54.48%. For EPS growth, Alnylam Pharmaceuticals, Inc. has seen a growth of 28.80%, and is looking to grow in the next year to -7.50%. More long term stats show that EPS growth has been -27.30% over the last five years and could be 46.09% for the next five years. Alnylam Pharmaceuticals, Inc. has seen sales growth quarter over quarter at 0.00%, with EPS growth quarter over quarter at -23.80%. The 20-day simple moving average is -48.41%, with the 200-day simple moving average coming to -46.34%.

Since the IPO date for Alnylam Pharmaceuticals, Inc. on the 06/01/2004, Alnylam Pharmaceuticals, Inc. has seen performance year to date to be -61.58%. With Alnylam Pharmaceuticals, Inc. trading at 35.45, the dividend yield is *TBA, and the EPS is -4.24.

So could Alnylam Pharmaceuticals, Inc., be undervalued? Well as said before P/E is *TBA. The PEG is *TBA, P/S is 109.57 and the P/B is at 2.82. The P/cash is 3.83, with P/free cash flow at *TBA.

Alnylam Pharmaceuticals, Inc. ability to deal with debt shows that the current ratio is 12.6, and the quick ratio is 12.6. This is with long term debt/equity at 0.14, and total debt/equity at 0.14.

In terms of margins, Alnylam Pharmaceuticals, Inc. has a gross margin of *TBA, an operating margin of *TBA and a profit margin of *TBA.Payout ratio for Alnylam Pharmaceuticals, Inc. is *TBA. Return on assets come to -26.10% with return on investment coming to -23.40%.

Insider ownership for Alnylam Pharmaceuticals, Inc., is at 0.20% and institutional ownership comes to 88.20%. Outstanding shares are at 90.58. While shares float is 71.17. The float short is currently 11.15%, and short ratio is 7.52.

Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.

About the author

Stephen Butters

Leave a Comment